Hepatocellular Cancer

P=N/A, N=107, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Aug 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026

P2, N=95, Recruiting, TaiRx, Inc. | Trial primary completion date: Sep 2025 --> Mar 2026

P=N/A, N=10000, Active, not recruiting, Target PharmaSolutions, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Feb 2026

P3, N=480, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Jun 2028 --> Aug 2025 | Trial completion date: Dec 2029 --> Mar 2026

P2/3, N=20, Recruiting, Eastern Hepatobiliary Surgery Hospital

In murine hepatocellular carcinoma models, treatment with the chimera significantly inhibited tumor growth, reduced angiogenesis, and prolonged survival. Our findings highlight a dual immune checkpoint-targeting strategy that integrates selective delivery with gene silencing, offering a tumor-specific, non-antibody approach for Treg depletion and a promising avenue for solid tumor immunotherapy.

Interestingly, overexpression of SLC1A5 reversed the efficacy of celastrol in decreasing glutamine metabolic flux to suppress the malignant proliferation of hepatoma cells in vitro and in vivo. Overall, this study provides compelling evidence to demonstrate the efficacy of celastrol in inhibiting hepatocarcinogenesis by suppressing SLC1A5-mediated glutamine dependence, suggesting that celastrol as a natural active compound is expected to be developed as a therapeutic agent for HCC.

Our findings demonstrate that US-activated piezoelectric BZT nanocubes exert potent antitumor effects through direct piezoelectric catalysis and, more importantly, through the remodeling of the TME via the calcium/NF-κB pathway. This study highlights the great potential of piezoelectric nanomaterials as a multifaceted and immunomodulatory strategy for cancer therapy.

By enabling automated analysis of FRET images, FRET-SAM significantly enhances the efficiency and accuracy of FRET two-hybrid assays, while eliminating subjective bias. The capability of FRET-SAM to resolve drug-target interactions establishes it as a promising tool for drug discovery.

P=N/A, N=240, Recruiting, Assistance Publique - Hôpitaux de Paris | N=120 --> 240

P2, N=27, Not yet recruiting, Mayo Clinic